Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
4.740
-0.090 (-1.86%)
Dec 5, 2025, 4:00 PM EST - Market closed
Cellectis Employees
As of December 31, 2024, Cellectis had 222 total employees, including 216 full-time and 6 part-time employees. The number of employees increased by 1 or 0.45% compared to the previous year.
Employees
222
Change (1Y)
1
Growth (1Y)
0.45%
Revenue / Employee
$371,851
Profits / Employee
-$159,248
Market Cap
346.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLLS News
- 2 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 17 days ago - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells - GlobeNewsWire
- 4 weeks ago - Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Cellectis to Present a Development Update for eti-cel at ASH 2025 - GlobeNewsWire
- 5 weeks ago - Cellectis to Report Third Quarter Financial Results on November 7, 2025 - GlobeNewsWire
- 7 weeks ago - Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL - GlobeNewsWire
- 7 weeks ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 7 weeks ago - Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers - GlobeNewsWire